LDN-193189

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：LDN-193189	Purity：98% min
CAS NO：1062368-24-4	Solubility：Ethanol : 0.25 mg/mL (0.62 mM)
Molecular Formula：C₂₅H₂₂N₆	Package：Package according to customer requirements
Molecular Weight：406.482	Storage：Store at -20℃

Quality control

COA

Remarks

LDN-193189 (DM3189) is a selective BMP signaling inhibitor, inhibits the ALK1, ALK2, ALK3 and ALK6 with IC50s of 0.8 nM, 0.8 nM, 5.3 nM and 16.7 nM in the kinase assay, respectively. LDN-193189 inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50s of 5 nM and 30 nM in C2C12 cells, respectively, exhibits 200-fold selectivity for BMP versus TGF-β. For animal testing, the water-soluble S7507 LDN-193189 2HCl is recommended.

Chemical Name:

4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline

TGF-beta/Smad Inhibitors Related Products:

SB431542; Galunisertib; LY2109761; SB525334; SB-505124; GW788388; LY364947; RepSox; K02288; A-83-01; LDN-212854; PD169316; ITD-1; LY3200882; Dorsomorphin; Dorsomorphin 2HCl; Kartogenin

References

[1]. Yu PB, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med, 2008, 14(12), 1363-1369.

[2]. Lee YC, et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res, 2011, 71(15), 5194-5203.